ID   CRY1_HUMAN              Reviewed;         586 AA.
AC   Q16526;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JUN-2023, entry version 175.
DE   RecName: Full=Cryptochrome-1;
GN   Name=CRY1; Synonyms=PHLL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RC   TISSUE=Fibroblast;
RX   PubMed=8909283; DOI=10.1021/bi962209o;
RA   Hsu D.S., Zhao X., Zhao S., Kazantsev A., Wang R.-P., Todo T., Wei Y.-F.,
RA   Sancar A.;
RT   "Putative human blue-light photoreceptors hCRY1 and hCRY2 are
RT   flavoproteins.";
RL   Biochemistry 35:13871-13877(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=8921389; DOI=10.1006/geno.1996.0539;
RA   van der Spek P.J., Kobayashi K., Bootsma D., Takao M., Eker A.P.M.,
RA   Yasui A.;
RT   "Cloning, tissue expression, and mapping of a human photolyase homolog with
RT   similarity to plant blue-light receptors.";
RL   Genomics 37:177-182(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8600518; DOI=10.1126/science.272.5258.109;
RA   Todo T., Ryo H., Yamamoto K., Toh H., Inui T., Ayaki H., Nomura T.,
RA   Ikenaga M.;
RT   "Similarity among the Drosophila (6-4)photolyase, a human photolyase
RT   homolog, and the DNA photolyase-blue-light photoreceptor family.";
RL   Science 272:109-112(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=10531061; DOI=10.1126/science.286.5440.768;
RA   Griffin E.A. Jr., Staknis D., Weitz C.J.;
RT   "Light-independent role of CRY1 and CRY2 in the mammalian circadian
RT   clock.";
RL   Science 286:768-771(1999).
RN   [6]
RP   FUNCTION.
RX   PubMed=14672706; DOI=10.1016/j.bbrc.2003.11.099;
RA   Kawamoto T., Noshiro M., Sato F., Maemura K., Takeda N., Nagai R.,
RA   Iwata T., Fujimoto K., Furukawa M., Miyazaki K., Honma S., Honma K.I.,
RA   Kato Y.;
RT   "A novel autofeedback loop of Dec1 transcription involved in circadian
RT   rhythm regulation.";
RL   Biochem. Biophys. Res. Commun. 313:117-124(2004).
RN   [7]
RP   INTERACTION WITH PPP5C.
RX   PubMed=16790549; DOI=10.1073/pnas.0604138103;
RA   Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.;
RT   "Posttranslational regulation of the mammalian circadian clock by
RT   cryptochrome and protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY, UBIQUITINATION BY FBXL3, AND
RP   INTERACTION WITH FBXL3.
RX   PubMed=17463251; DOI=10.1126/science.1141194;
RA   Busino L., Bassermann F., Maiolica A., Lee C., Nolan P.M., Godinho S.I.,
RA   Draetta G.F., Pagano M.;
RT   "SCFFbxl3 controls the oscillation of the circadian clock by directing the
RT   degradation of cryptochrome proteins.";
RL   Science 316:900-904(2007).
RN   [9]
RP   INTERACTION WITH GNAS.
RX   PubMed=20852621; DOI=10.1038/nm.2214;
RA   Zhang E.E., Liu Y., Dentin R., Pongsawakul P.Y., Liu A.C., Hirota T.,
RA   Nusinow D.A., Sun X., Landais S., Kodama Y., Brenner D.A., Montminy M.,
RA   Kay S.A.;
RT   "Cryptochrome mediates circadian regulation of cAMP signaling and hepatic
RT   gluconeogenesis.";
RL   Nat. Med. 16:1152-1156(2010).
RN   [10]
RP   INTERACTION WITH PER2.
RX   PubMed=21613214; DOI=10.1074/jbc.m111.254680;
RA   Ye R., Selby C.P., Ozturk N., Annayev Y., Sancar A.;
RT   "Biochemical analysis of the canonical model for the mammalian circadian
RT   clock.";
RL   J. Biol. Chem. 286:25891-25902(2011).
RN   [11]
RP   FUNCTION AS NR3C1 REPRESSOR, AND INTERACTION WITH AR; NR1D1; NR3C1; RORA
RP   AND RORC.
RX   PubMed=22170608; DOI=10.1038/nature10700;
RA   Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W.,
RA   Downes M., Evans R.M.;
RT   "Cryptochromes mediate rhythmic repression of the glucocorticoid
RT   receptor.";
RL   Nature 480:552-556(2011).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH PRMT5.
RX   PubMed=23133559; DOI=10.1371/journal.pone.0048152;
RA   Na J., Lee K., Kim H.G., Shin J.Y., Na W., Jeong H., Lee J.W., Cho S.,
RA   Kim W.S., Ju B.G.;
RT   "Role of type II protein arginine methyltransferase 5 in the regulation of
RT   Circadian Per1 gene.";
RL   PLoS ONE 7:E48152-E48152(2012).
RN   [13]
RP   ACTIVITY REGULATION, SUBCELLULAR LOCATION, UBIQUITINATION, AND MUTAGENESIS
RP   OF ASP-387 AND ASN-393.
RX   PubMed=22798407; DOI=10.1126/science.1223710;
RA   Hirota T., Lee J.W., St John P.C., Sawa M., Iwaisako K., Noguchi T.,
RA   Pongsawakul P.Y., Sonntag T., Welsh D.K., Brenner D.A., Doyle F.J. III,
RA   Schultz P.G., Kay S.A.;
RT   "Identification of small molecule activators of cryptochrome.";
RL   Science 337:1094-1097(2012).
RN   [14]
RP   REVIEW.
RX   PubMed=23303907; DOI=10.1152/physrev.00016.2012;
RA   Eckel-Mahan K., Sassone-Corsi P.;
RT   "Metabolism and the circadian clock converge.";
RL   Physiol. Rev. 93:107-135(2013).
RN   [15]
RP   REVIEW.
RX   PubMed=23916625; DOI=10.1016/j.tcb.2013.07.002;
RA   Partch C.L., Green C.B., Takahashi J.S.;
RT   "Molecular architecture of the mammalian circadian clock.";
RL   Trends Cell Biol. 24:90-99(2014).
RN   [16]
RP   INTERACTION WITH DDB1-CUE4A COMPLEX AND DTL, AND SUBCELLULAR LOCATION.
RX   PubMed=26431207; DOI=10.1371/journal.pone.0139725;
RA   Tong X., Zhang D., Guha A., Arthurs B., Cazares V., Gupta N., Yin L.;
RT   "CUL4-DDB1-CDT2 E3 ligase regulates the molecular clock activity by
RT   promoting ubiquitination-dependent degradation of the mammalian CRY1.";
RL   PLoS ONE 10:E0139725-E0139725(2015).
RN   [17]
RP   UBIQUITINATION.
RX   PubMed=27565346; DOI=10.1016/j.cell.2016.07.027;
RA   Scott D.C., Rhee D.Y., Duda D.M., Kelsall I.R., Olszewski J.L., Paulo J.A.,
RA   de Jong A., Ovaa H., Alpi A.F., Harper J.W., Schulman B.A.;
RT   "Two distinct types of E3 ligases work in unison to regulate substrate
RT   ubiquitylation.";
RL   Cell 166:1198-1214(2016).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CLOCK-BMAL1, AND
RP   INVOLVEMENT IN DSPS.
RX   PubMed=28388406; DOI=10.1016/j.cell.2017.03.027;
RA   Patke A., Murphy P.J., Onat O.E., Krieger A.C., Oezcelik T., Campbell S.S.,
RA   Young M.W.;
RT   "Mutation of the human circadian clock gene CRY1 in familial delayed sleep
RT   phase disorder.";
RL   Cell 169:203-215(2017).
RN   [19]
RP   INTERACTION WITH HNF4A.
RX   PubMed=30530698; DOI=10.1073/pnas.1816411115;
RA   Qu M., Duffy T., Hirota T., Kay S.A.;
RT   "Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-
RT   specific circadian networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E12305-E12312(2018).
CC   -!- FUNCTION: Transcriptional repressor which forms a core component of the
CC       circadian clock. The circadian clock, an internal time-keeping system,
CC       regulates various physiological processes through the generation of
CC       approximately 24 hour circadian rhythms in gene expression, which are
CC       translated into rhythms in metabolism and behavior. It is derived from
CC       the Latin roots 'circa' (about) and 'diem' (day) and acts as an
CC       important regulator of a wide array of physiological functions
CC       including metabolism, sleep, body temperature, blood pressure,
CC       endocrine, immune, cardiovascular, and renal function. Consists of two
CC       major components: the central clock, residing in the suprachiasmatic
CC       nucleus (SCN) of the brain, and the peripheral clocks that are present
CC       in nearly every tissue and organ system. Both the central and
CC       peripheral clocks can be reset by environmental cues, also known as
CC       Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the
CC       central clock is light, which is sensed by retina and signals directly
CC       to the SCN. The central clock entrains the peripheral clocks through
CC       neuronal and hormonal signals, body temperature and feeding-related
CC       cues, aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression to
CC       create a peak of protein expression once every 24 hours to control when
CC       a particular physiological process is most active with respect to the
CC       solar day. Transcription and translation of core clock components
CC       (CLOCK, NPAS2, BMAL1, BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a
CC       critical role in rhythm generation, whereas delays imposed by post-
CC       translational modifications (PTMs) are important for determining the
CC       period (tau) of the rhythms (tau refers to the period of a rhythm and
CC       is the length, in time, of one complete cycle). A diurnal rhythm is
CC       synchronized with the day/night cycle, while the ultradian and
CC       infradian rhythms have a period shorter and longer than 24 hours,
CC       respectively. Disruptions in the circadian rhythms contribute to the
CC       pathology of cardiovascular diseases, cancer, metabolic syndromes and
CC       aging. A transcription/translation feedback loop (TTFL) forms the core
CC       of the molecular circadian clock mechanism. Transcription factors,
CC       CLOCK or NPAS2 and BMAL1 or BMAL2, form the positive limb of the
CC       feedback loop, act in the form of a heterodimer and activate the
CC       transcription of core clock genes and clock-controlled genes (involved
CC       in key metabolic processes), harboring E-box elements (5'-CACGTG-3')
CC       within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which
CC       are transcriptional repressors form the negative limb of the feedback
CC       loop and interact with the CLOCK|NPAS2-BMAL1|BMAL2 heterodimer
CC       inhibiting its activity and thereby negatively regulating their own
CC       expression. This heterodimer also activates nuclear receptors NR1D1/2
CC       and RORA/B/G, which form a second feedback loop and which activate and
CC       repress BMAL1 transcription, respectively. CRY1 and CRY2 have redundant
CC       functions but also differential and selective contributions at least in
CC       defining the pace of the SCN circadian clock and its circadian
CC       transcriptional outputs. More potent transcriptional repressor in
CC       cerebellum and liver than CRY2, though more effective in lengthening
CC       the period of the SCN oscillator. On its side, CRY2 seems to play a
CC       critical role in tuning SCN circadian period by opposing the action of
CC       CRY1. With CRY2, is dispensable for circadian rhythm generation but
CC       necessary for the development of intercellular networks for rhythm
CC       synchrony. Capable of translocating circadian clock core proteins such
CC       as PER proteins to the nucleus. Interacts with CLOCK-BMAL1
CC       independently of PER proteins and is found at CLOCK-BMAL1-bound sites,
CC       suggesting that CRY may act as a molecular gatekeeper to maintain
CC       CLOCK-BMAL1 in a poised and repressed state until the proper time for
CC       transcriptional activation. Represses the CLOCK-BMAL1 induced
CC       transcription of BHLHE40/DEC1. Represses the CLOCK-BMAL1 induced
CC       transcription of ATF4, MTA1, KLF10 and NAMPT (By similarity). May
CC       repress circadian target genes expression in collaboration with HDAC1
CC       and HDAC2 through histone deacetylation. Mediates the clock-control
CC       activation of ATR and modulates ATR-mediated DNA damage checkpoint. In
CC       liver, mediates circadian regulation of cAMP signaling and
CC       gluconeogenesis by binding to membrane-coupled G proteins and blocking
CC       glucagon-mediated increases in intracellular cAMP concentrations and
CC       CREB1 phosphorylation. Inhibits hepatic gluconeogenesis by decreasing
CC       nuclear FOXO1 levels that down-regulates gluconeogenic gene expression
CC       (By similarity). Besides its role in the maintenance of the circadian
CC       clock, is also involved in the regulation of other processes. Represses
CC       glucocorticoid receptor NR3C1/GR-induced transcriptional activity by
CC       binding to glucocorticoid response elements (GREs). Plays a key role in
CC       glucose and lipid metabolism modulation, in part, through the
CC       transcriptional regulation of genes involved in these pathways, such as
CC       LEP or ACSL4 (By similarity). Represses PPARD and its target genes in
CC       the skeletal muscle and limits exercise capacity (By similarity). Plays
CC       an essential role in the generation of circadian rhythms in the retina
CC       (By similarity). Represses the transcriptional activity of NR1I2 (By
CC       similarity). {ECO:0000250|UniProtKB:P97784,
CC       ECO:0000269|PubMed:10531061, ECO:0000269|PubMed:14672706,
CC       ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:23133559,
CC       ECO:0000269|PubMed:28388406}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000250|UniProtKB:P97784};
CC       Note=Binds 1 FAD per subunit. Only a minority of the protein molecules
CC       contain bound FAD. Contrary to the situation in photolyases, the FAD is
CC       bound in a shallow, surface-exposed pocket.
CC       {ECO:0000250|UniProtKB:P97784};
CC   -!- COFACTOR:
CC       Name=(6R)-5,10-methylene-5,6,7,8-tetrahydrofolate;
CC         Xref=ChEBI:CHEBI:15636;
CC       Note=Binds 1 5,10-methenyltetrahydrofolate (MTHF) non-covalently per
CC       subunit.;
CC   -!- ACTIVITY REGULATION: KL001 (N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-
CC       (2-furanylmethyl)-methanesulfonamide) binds to CRY1 and stabilizes it
CC       by inhibiting FBXL3- and ubiquitin-dependent degradation of CRY1
CC       resulting in lengthening of the circadian periods.
CC       {ECO:0000269|PubMed:22798407}.
CC   -!- SUBUNIT: Component of the circadian core oscillator, which includes the
CC       CRY proteins, CLOCK or NPAS2, BMAL1 or BMAL2, CSNK1D and/or CSNK1E,
CC       TIMELESS, and the PER proteins (By similarity). Interacts directly with
CC       TIMELESS (By similarity). Interacts directly with PER1 and PER3 (By
CC       similarity). Interacts directly with PER2; interaction with PER2
CC       inhibits its ubiquitination and vice versa (PubMed:21613214). Interacts
CC       with FBXL21 (By similarity). Interacts with FBXL3 (PubMed:17463251).
CC       Interacts with PPP5C (via TPR repeats) (PubMed:16790549). Interacts
CC       with CLOCK-BMAL1 independently of PER2 and DNA (PubMed:28388406).
CC       Interacts with HDAC1, HDAC2 and SIN3B. Interacts with nuclear receptors
CC       AR, NR1D1, NR3C1/GR, RORA and RORC; the interaction with at least
CC       NR3C1/GR is ligand dependent (PubMed:22170608). Interacts with PRKDC
CC       (By similarity). Interacts with the G protein subunit alpha GNAS; the
CC       interaction may block GPCR-mediated regulation of cAMP concentrations
CC       (PubMed:20852621). Interacts with PRMT5 (PubMed:23133559). Interacts
CC       with EZH2 (By similarity). Interacts with MYBBP1A, DOCK7, HNRNPU,
CC       RPL7A, RPL8 and RPS3 (By similarity). Interacts with MAP1LC3B (By
CC       similarity). Interacts with CLOCK (By similarity). Interacts with BMAL1
CC       (By similarity). Interacts weakly with HDAC3; this interaction is
CC       enhanced in the presence of FBXL3 (By similarity). Interacts with
CC       TRIM28, KCTD5 and DDB1 (By similarity). Interacts with FOXO1 (By
CC       similarity). Interacts with DTL and DDB1-CUL4A complex
CC       (PubMed:26431207). Interacts with HNF4A (PubMed:30530698). Interacts
CC       with PSMD2 in a KDM8-dependent manner (By similarity). Interacts with
CC       KDM8 in a FBXL3-dependent manner (By similarity). Interacts with PPARG
CC       in a ligand-dependent manner (By similarity). Interacts with PPARD (via
CC       domain NR LBD) and NR1I2 (via domain NR LBD) in a ligand-dependent
CC       manner (By similarity). Interacts with PPARA, NR1I3 and VDR (By
CC       similarity). {ECO:0000250|UniProtKB:P97784,
CC       ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:17463251,
CC       ECO:0000269|PubMed:20852621, ECO:0000269|PubMed:21613214,
CC       ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:23133559,
CC       ECO:0000269|PubMed:26431207, ECO:0000269|PubMed:28388406,
CC       ECO:0000269|PubMed:30530698}.
CC   -!- INTERACTION:
CC       Q16526; O14744: PRMT5; NbExp=3; IntAct=EBI-741297, EBI-351098;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000269|PubMed:22798407,
CC       ECO:0000269|PubMed:26431207, ECO:0000269|PubMed:28388406}.
CC       Note=Translocated to the nucleus through interaction with other clock
CC       proteins such as PER2 or BMAL1. {ECO:0000250|UniProtKB:P97784}.
CC   -!- INDUCTION: Expression is regulated by light and circadian rhythms and
CC       osicllates diurnally. Peak expression in the suprachiasma nucleus (SCN)
CC       and eye at the day/night transition (CT12). Levels decrease with BMAL1-
CC       CLOCK inhibition as part of the autoregulatory feedback loop.
CC   -!- DOMAIN: The LIR motifs (LC3-interacting region) 3 and 5 are required
CC       for its interaction with MAP1LC3B and for its autophagy-mediated
CC       degradation. {ECO:0000250|UniProtKB:P97784}.
CC   -!- PTM: Phosphorylation on Ser-247 by MAPK is important for the inhibition
CC       of CLOCK-BMAL1-mediated transcriptional activity. Phosphorylation by
CC       CSNK1E requires interaction with PER1 or PER2. Phosphorylation at Ser-
CC       71 and Ser-280 by AMPK decreases protein stability. Phosphorylation at
CC       Ser-568 exhibits a robust circadian rhythm with a peak at CT8,
CC       increases protein stability, prevents SCF(FBXL3)-mediated degradation
CC       and is antagonized by interaction with PRKDC.
CC       {ECO:0000250|UniProtKB:P97784}.
CC   -!- PTM: Ubiquitinated by the SCF(FBXL3) and SCF(FBXL21) complexes,
CC       regulating the balance between degradation and stabilization. The
CC       SCF(FBXL3) complex is mainly nuclear and mediates ubiquitination and
CC       subsequent degradation of CRY1. In contrast, cytoplasmic SCF(FBXL21)
CC       complex-mediated ubiquitination leads to stabilize CRY1 and counteract
CC       the activity of the SCF(FBXL3) complex. The SCF(FBXL3) and SCF(FBXL21)
CC       complexes probably mediate ubiquitination at different Lys residues.
CC       Ubiquitination at Lys-11 and Lys-107 are specifically ubiquitinated by
CC       the SCF(FBXL21) complex but not by the SCF(FBXL3) complex.
CC       Ubiquitination may be inhibited by PER2 (PubMed:17463251,
CC       PubMed:22798407, PubMed:27565346). Deubiquitinated by USP7 (By
CC       similarity). {ECO:0000250|UniProtKB:P97784,
CC       ECO:0000269|PubMed:17463251, ECO:0000269|PubMed:22798407,
CC       ECO:0000269|PubMed:27565346}.
CC   -!- PTM: Undergoes autophagy-mediated degradation in the liver in a time-
CC       dependent manner. Autophagic degradation of CRY1 (an inhibitor of
CC       gluconeogenesis) occurs during periods of reduced feeding allowing
CC       induction of gluconeogenesis and maintenance of blood glucose levels.
CC       {ECO:0000250|UniProtKB:P97784}.
CC   -!- DISEASE: Delayed sleep phase syndrome (DSPS) [MIM:614163]: A circadian
CC       rhythm sleep disorder characterized by sleep-onset insomnia and
CC       difficulty in awakening at the desired time. Patients with DSPS have
CC       chronic difficulty in adjusting their sleep-onset and wake-up times to
CC       occupational, school, and social activities.
CC       {ECO:0000269|PubMed:28388406}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC       An adenine-to-cytosine transversion within the 5'splice site following
CC       exon 11 has been found in multiple members of a DSPD family and
CC       segregates with the disorder with autosomal dominant inheritance
CC       pattern. This variant is predicted to cause exon 11 skipping and in-
CC       frame deletion of 24 residues in the C-terminal region of CRY1.
CC       Functional studies show that the mutated protein acts as a more potent
CC       transcriptional repressor than wild-type, causes reduced expression of
CC       key transcriptional targets and lengthens the period of circadian
CC       molecular rhythms. {ECO:0000269|PubMed:28388406}.
CC   -!- SIMILARITY: Belongs to the DNA photolyase class-1 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cryptochrome entry;
CC       URL="https://en.wikipedia.org/wiki/Cryptochrome";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D84657; BAA12710.1; -; mRNA.
DR   EMBL; D83702; BAA12068.1; -; mRNA.
DR   EMBL; BC030519; AAH30519.1; -; mRNA.
DR   CCDS; CCDS9112.1; -.
DR   RefSeq; NP_004066.1; NM_004075.4.
DR   AlphaFoldDB; Q16526; -.
DR   SMR; Q16526; -.
DR   BioGRID; 107797; 156.
DR   ComplexPortal; CPX-3219; Cry1-Per2 complex.
DR   ComplexPortal; CPX-3222; Cry1-Per1 complex.
DR   ComplexPortal; CPX-3223; Cry1-Per3 complex.
DR   CORUM; Q16526; -.
DR   DIP; DIP-56602N; -.
DR   IntAct; Q16526; 127.
DR   MINT; Q16526; -.
DR   STRING; 9606.ENSP00000008527; -.
DR   ChEMBL; CHEMBL4296246; -.
DR   GuidetoPHARMACOLOGY; 2876; -.
DR   iPTMnet; Q16526; -.
DR   PhosphoSitePlus; Q16526; -.
DR   BioMuta; CRY1; -.
DR   DMDM; 74735764; -.
DR   EPD; Q16526; -.
DR   jPOST; Q16526; -.
DR   MassIVE; Q16526; -.
DR   MaxQB; Q16526; -.
DR   PaxDb; Q16526; -.
DR   PeptideAtlas; Q16526; -.
DR   ProteomicsDB; 60893; -.
DR   Antibodypedia; 3122; 340 antibodies from 35 providers.
DR   DNASU; 1407; -.
DR   Ensembl; ENST00000008527.10; ENSP00000008527.5; ENSG00000008405.12.
DR   GeneID; 1407; -.
DR   KEGG; hsa:1407; -.
DR   MANE-Select; ENST00000008527.10; ENSP00000008527.5; NM_004075.5; NP_004066.1.
DR   UCSC; uc001tmi.5; human.
DR   AGR; HGNC:2384; -.
DR   CTD; 1407; -.
DR   DisGeNET; 1407; -.
DR   GeneCards; CRY1; -.
DR   HGNC; HGNC:2384; CRY1.
DR   HPA; ENSG00000008405; Low tissue specificity.
DR   MalaCards; CRY1; -.
DR   MIM; 601933; gene.
DR   MIM; 614163; phenotype.
DR   neXtProt; NX_Q16526; -.
DR   OpenTargets; ENSG00000008405; -.
DR   PharmGKB; PA26904; -.
DR   VEuPathDB; HostDB:ENSG00000008405; -.
DR   eggNOG; KOG0133; Eukaryota.
DR   GeneTree; ENSGT00940000155455; -.
DR   HOGENOM; CLU_010348_3_4_1; -.
DR   InParanoid; Q16526; -.
DR   OMA; WQQELAW; -.
DR   OrthoDB; 124765at2759; -.
DR   PhylomeDB; Q16526; -.
DR   TreeFam; TF323191; -.
DR   PathwayCommons; Q16526; -.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SignaLink; Q16526; -.
DR   SIGNOR; Q16526; -.
DR   BioGRID-ORCS; 1407; 8 hits in 1161 CRISPR screens.
DR   ChiTaRS; CRY1; human.
DR   GenomeRNAi; 1407; -.
DR   Pharos; Q16526; Tchem.
DR   PRO; PR:Q16526; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q16526; protein.
DR   Bgee; ENSG00000008405; Expressed in oocyte and 206 other tissues.
DR   ExpressionAtlas; Q16526; baseline and differential.
DR   Genevisible; Q16526; HS.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0009882; F:blue light photoreceptor activity; NAS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0070888; F:E-box binding; IEA:Ensembl.
DR   GO; GO:0071949; F:FAD binding; IBA:GO_Central.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0009785; P:blue light signaling pathway; NAS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0042754; P:negative regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045744; P:negative regulation of G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2000850; P:negative regulation of glucocorticoid secretion; IEA:Ensembl.
DR   GO; GO:0045721; P:negative regulation of gluconeogenesis; ISS:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000001; P:regulation of DNA damage checkpoint; ISS:UniProtKB.
DR   GO; GO:0014823; P:response to activity; ISS:UniProtKB.
DR   GO; GO:0033762; P:response to glucagon; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; ISS:UniProtKB.
DR   GO; GO:0061912; P:selective autophagy; IEA:Ensembl.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; ISS:UniProtKB.
DR   Gene3D; 1.25.40.80; -; 2.
DR   Gene3D; 1.10.579.10; DNA Cyclobutane Dipyrimidine Photolyase, subunit A, domain 3; 1.
DR   Gene3D; 3.40.50.620; HUPs; 1.
DR   InterPro; IPR036134; Crypto/Photolyase_FAD-like_sf.
DR   InterPro; IPR036155; Crypto/Photolyase_N_sf.
DR   InterPro; IPR005101; Cryptochr/Photolyase_FAD-bd.
DR   InterPro; IPR002081; Cryptochrome/DNA_photolyase_1.
DR   InterPro; IPR006050; DNA_photolyase_N.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   PANTHER; PTHR11455; CRYPTOCHROME; 1.
DR   PANTHER; PTHR11455:SF16; CRYPTOCHROME-1; 1.
DR   Pfam; PF00875; DNA_photolyase; 1.
DR   Pfam; PF03441; FAD_binding_7; 1.
DR   SUPFAM; SSF48173; Cryptochrome/photolyase FAD-binding domain; 1.
DR   SUPFAM; SSF52425; Cryptochrome/photolyase, N-terminal domain; 1.
DR   PROSITE; PS51645; PHR_CRY_ALPHA_BETA; 1.
PE   1: Evidence at protein level;
KW   Biological rhythms; Chromophore; Cytoplasm; FAD; Flavoprotein;
KW   Isopeptide bond; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Photoreceptor protein; Receptor; Reference proteome; Repressor;
KW   Sensory transduction; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..586
FT                   /note="Cryptochrome-1"
FT                   /id="PRO_0000261140"
FT   DOMAIN          3..132
FT                   /note="Photolyase/cryptochrome alpha/beta"
FT   REGION          371..470
FT                   /note="Required for inhibition of CLOCK-BMAL1-mediated
FT                   transcription"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   REGION          471..493
FT                   /note="Interaction with TIMELESS"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   REGION          552..586
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           50..54
FT                   /note="LIR 1"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           82..87
FT                   /note="LIR 2"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           151..156
FT                   /note="LIR 3"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           255..260
FT                   /note="LIR 4"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           271..276
FT                   /note="LIR 5"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           285..290
FT                   /note="LIR 6"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           335..339
FT                   /note="LIR 7"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           379..384
FT                   /note="LIR 8"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           395..400
FT                   /note="LIR 9"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           411..416
FT                   /note="LIR 10"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           430..435
FT                   /note="LIR 11"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           486..491
FT                   /note="LIR 12"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOTIF           492..497
FT                   /note="LIR 13"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   BINDING         252
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   BINDING         289
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   BINDING         355
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   BINDING         387..389
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         71
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         247
FT                   /note="Phosphoserine; by MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         280
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         568
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        11
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        107
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        159
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        329
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        485
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        565
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MUTAGEN         387
FT                   /note="D->N: Loss of binding to KL001."
FT                   /evidence="ECO:0000269|PubMed:22798407"
FT   MUTAGEN         393
FT                   /note="N->D: Loss of binding to KL001."
FT                   /evidence="ECO:0000269|PubMed:22798407"
SQ   SEQUENCE   586 AA;  66395 MW;  96A5B09A6364D3B9 CRC64;
     MGVNAVHWFR KGLRLHDNPA LKECIQGADT IRCVYILDPW FAGSSNVGIN RWRFLLQCLE
     DLDANLRKLN SRLFVIRGQP ADVFPRLFKE WNITKLSIEY DSEPFGKERD AAIKKLATEA
     GVEVIVRISH TLYDLDKIIE LNGGQPPLTY KRFQTLISKM EPLEIPVETI TSEVIEKCTT
     PLSDDHDEKY GVPSLEELGF DTDGLSSAVW PGGETEALTR LERHLERKAW VANFERPRMN
     ANSLLASPTG LSPYLRFGCL SCRLFYFKLT DLYKKVKKNS SPPLSLYGQL LWREFFYTAA
     TNNPRFDKME GNPICVQIPW DKNPEALAKW AEGRTGFPWI DAIMTQLRQE GWIHHLARHA
     VACFLTRGDL WISWEEGMKV FEELLLDADW SINAGSWMWL SCSSFFQQFF HCYCPVGFGR
     RTDPNGDYIR RYLPVLRGFP AKYIYDPWNA PEGIQKVAKC LIGVNYPKPM VNHAEASRLN
     IERMKQIYQQ LSRYRGLGLL ASVPSNPNGN GGFMGYSAEN IPGCSSSGSC SQGSGILHYA
     HGDSQQTHLL KQGRSSMGTG LSGGKRPSQE EDTQSIGPKV QRQSTN
//
